PCI BIOTECH HOLDING ASA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.618 NOK | -0.12% |
|
-4.82% | -22.77% |
Presenter SpeechHans Bohn (Executives)Second quarter presentation. I'm Hans Peter Bøhn, I'm th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
PCI Biotech Holding ASA is a cancer focused biopharmaceutical company based in Norway. The Company is developing therapeutic products based on its photochemical internalisation (PCI) technology. PCI Biotechâs product is the photosensitiser fimaporfin (Amphinex). The PCI technology can enhance the effect of anticancer drugs by targeted, light-directed drug delivery into cancer cells, and can also be used as a platform that may both potentiate the effect of vaccines and enable macromolecules to reach intracellular targets. The PCI technology platform consists of two elements: a small molecule photosensitiser (named fimaporfin) and a light source. The primary aim of PCI is to introduce drug molecules or macromolecules into the cytosol of the target cells. It is this drug or macromolecule that gives the biological effect in a PCI treatment, and the intended biological effect may range from cell killing, through modification of gene expression to enhanced antigen presentation.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -22.77% | 5.47M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- Transcript : PCI Biotech Holding ASA, Q2 2022 Earnings Call, Aug 31, 2022
